Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Pheochromocytoma
Stage/Subtype:  recurrent pheochromocytoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-7 of 7 for your search:
Start Over
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PEN-221-001, NCI-2017-00043, NCT02936323
Iobenguane I-131 in Treating Patients with Recurrent Neuroblastoma, Malignant Pheochromocytoma, or Malignant Paraganglioma
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 1
Trial IDs: 04-148, NCI-2016-00955, MSKCC-04148, NCT00107289
Cabozantinib S-malate in Treating Patients with Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0081, NCI-2014-02607, NCT02302833
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1609, NCI-2016-01041, NCT02834013
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CPDR001E2201, NCI-2017-00420, 2016-002522-36, NCT02955069
Iobenguane I 131 in Treating Patients with Relapsed or Refractory Neuroblastoma or Metastatic Pheochromocytoma
Status: Active
Phase: No phase specified
Type: Supportive care, Treatment
Age: 1 and over
Trial IDs: 2012LS107, NCI-2013-01933, NCT01850888
Expanded Access Protocol Using I131-MIBG
Status: Active
Phase: No phase specified
Type: Treatment
Age: 12 months and over
Trial IDs: JDI2007-01, NCI-2014-01104, NCT01590680
Start Over